Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aripiprazole

FDA-approved product (tablet, oral), marketed as Abilify, Abilify Asimtufii, Abilify Maintena Kit and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Aripiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Agitation
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Depressive disorder
  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aripiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aripiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Aripiprazole in Late Life Bipolar Disorder

    NCT00194038 · start 2004-04

    Registered record
    Registry ID
    NCT00194038
    Conditions
    Bipolar Disorder
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-04
    Completion
    2006-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAripiprazole
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

    NCT00223418 · start 2004-01

    Registered record
    Registry ID
    NCT00223418
    Conditions
    Schizophenia Disorder; Schizoaffective Disorder
    Interventions
    aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-01
    Completion
    2007-06
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophenia Disorder; Schizoaffective Disorder
    Interventionaripiprazole
    PhaseNot applicable
    Registry statusCompleted

  • Risperdal Consta for Bipolar Disorder

    NCT00177164 · start 2003-11

    Registered record
    Registry ID
    NCT00177164
    Conditions
    Bipolar I Disorder
    Interventions
    Injectable Risperidone (Consta) or oral antipsychotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-11
    Completion
    2009-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionInjectable Risperidone (Consta) or oral antipsychotic
    PhasePhase 3
    Registry statusCompleted

  • Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

    NCT00095810 · start 2003-07

    Registered record
    Registry ID
    NCT00095810
    Conditions
    Parkinson's Disease; Psychoses
    Interventions
    aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-07
    Completion
    2004-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Psychoses
    Interventionaripiprazole
    PhasePhase 4
    Registry statusCompleted

  • Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

    NCT00046384 · start 2002-06

    Registered record
    Registry ID
    NCT00046384
    Conditions
    Bipolar I Disorder
    Interventions
    aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-06
    Completion
    2003-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    Interventionaripiprazole
    PhasePhase 3
    Registry statusCompleted